118 related articles for article (PubMed ID: 25693084)
21. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
22. Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma.
Holten-Andersen MN; Hansen U; Brünner N; Nielsen HJ; Illemann M; Nielsen BS
Int J Cancer; 2005 Jan; 113(2):198-206. PubMed ID: 15386409
[TBL] [Abstract][Full Text] [Related]
23. Plasma or serum TIMP-1 is a predictor of survival outcomes in colorectal cancer: a meta-analysis.
Lee JH; Choi JW; Kim YS
J Gastrointestin Liver Dis; 2011 Sep; 20(3):287-91. PubMed ID: 21961097
[TBL] [Abstract][Full Text] [Related]
24. Plasma Levels and Diagnostic Utility of Macrophage Colony-Stimulating Factor, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinases-1 as New Biomarkers of Breast Cancer.
Ławicki S; Głażewska EK; Sobolewska M; Będkowska GE; Szmitkowski M
Ann Lab Med; 2016 May; 36(3):223-9. PubMed ID: 26915610
[TBL] [Abstract][Full Text] [Related]
25. Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients.
Waas ET; Hendriks T; Lomme RM; Wobbes T
Dis Colon Rectum; 2005 Apr; 48(4):700-10. PubMed ID: 15906450
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.
Wu ZS; Wu Q; Yang JH; Wang HQ; Ding XD; Yang F; Xu XC
Int J Cancer; 2008 May; 122(9):2050-6. PubMed ID: 18172859
[TBL] [Abstract][Full Text] [Related]
27. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer.
Holten-Andersen MN; Murphy G; Nielsen HJ; Pedersen AN; Christensen IJ; Høyer-Hansen G; Brünner N; Stephens RW
Br J Cancer; 1999 May; 80(3-4):495-503. PubMed ID: 10408859
[TBL] [Abstract][Full Text] [Related]
28. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
29. Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals.
Nielsen HJ; Brünner N; Jorgensen LN; Olsen J; Rahr HB; Thygesen K; Hoyer U; Laurberg S; Stieber P; Blankenstein MA; Davis G; Dowell BL; Christensen IJ; ;
Scand J Gastroenterol; 2011 Jan; 46(1):60-9. PubMed ID: 20799911
[TBL] [Abstract][Full Text] [Related]
30. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer.
Ylisirniö S; Höyhtyä M; Mäkitaro R; Pääakkö P; Risteli J; Kinnula VL; Turpeenniemi-Hujanen T; Jukkola A
Clin Cancer Res; 2001 Jun; 7(6):1633-7. PubMed ID: 11410500
[TBL] [Abstract][Full Text] [Related]
31. Altered plasma matrix metalloproteinase-9/tissue inhibitor of matrix [corrected] metalloproteinase-1 concentration during the early postoperative period in patients with colorectal cancer.
Kirman I; Jain S; Cekic V; Belizon A; Balik E; Sylla P; Arnell T; Forde KA; Whelan RL
Surg Endosc; 2006 Mar; 20(3):482-6. PubMed ID: 16432654
[TBL] [Abstract][Full Text] [Related]
32. Preoperative plasma TIMP-1 is an independent prognostic indicator in patients with primary colorectal cancer: a prospective validation study.
Birgisson H; Nielsen HJ; Christensen IJ; Glimelius B; Brünner N
Eur J Cancer; 2010 Dec; 46(18):3323-31. PubMed ID: 20619633
[TBL] [Abstract][Full Text] [Related]
33. Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples.
Pesta M; Holubec L; Topolcan O; Cerna M; Rupert K; Holubec LS; Treska V; Kormunda S; Elgrova L; Finek J; Cerny R
Anticancer Res; 2005; 25(5):3387-91. PubMed ID: 16101153
[TBL] [Abstract][Full Text] [Related]
34. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker.
Wang CS; Wu TL; Tsao KC; Sun CF
Ann Clin Lab Sci; 2006; 36(1):23-30. PubMed ID: 16501233
[TBL] [Abstract][Full Text] [Related]
35. High serum TIMP-1 correlates with poor prognosis in breast carcinoma - a validation study.
Kuvaja P; Würtz SØ; Talvensaari-Mattila A; Brünner N; Pääkkö P; Turpeenniemi-Hujanen T
Cancer Biomark; 2007; 3(6):293-300. PubMed ID: 18048967
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical expression of MMP-7 protein and its serum level in colorectal cancer.
Pryczynicz A; Gryko M; Niewiarowska K; Dymicka-Piekarska V; Ustymowicz M; Hawryluk M; Cepowicz D; Borsuk A; Kemona A; Famulski W; Guzinska-Ustymowicz K
Folia Histochem Cytobiol; 2013; 51(3):206-12. PubMed ID: 24203626
[TBL] [Abstract][Full Text] [Related]
37. Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with colorectal cancer.
Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Takemiya S; Yanoma S; Imada T; Noguchi Y
Anticancer Res; 2004; 24(3b):2101-5. PubMed ID: 15274408
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic value of platelet derived growth factor-BB, transforming growth factor-beta1, matrix metalloproteinase-1, and tissue inhibitor of matrix metalloproteinase-1 in serum and peripheral blood mononuclear cells for hepatic fibrosis.
Zhang BB; Cai WM; Weng HL; Hu ZR; Lu J; Zheng M; Liu RH
World J Gastroenterol; 2003 Nov; 9(11):2490-6. PubMed ID: 14606082
[TBL] [Abstract][Full Text] [Related]
39. [Expression of tissue inhibitor of metalloproteinase-1 in colorectal carcinoma and its clinical implications].
Liu Y; Jiang B; Tong HS; Lai XR
Nan Fang Yi Ke Da Xue Xue Bao; 2006 May; 26(5):699-700. PubMed ID: 16762889
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathologic and Prognostic Significance of Metalloproteinase Tissue Inhibitor-2 Promoters in Tunisian Colorectal Cancer: A Case-Control Study.
Ben Néjima D; Ben Zarkouna Y; Pujol P; Gammoudi A; Boussen H; Manai M
Appl Immunohistochem Mol Morphol; 2016 Sep; 24(8):583-8. PubMed ID: 26808125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
